Asthma Allergy Immunology

Asthma Allergy Immunology

2020, Vol 18, Num, 4     (Pages: 027-029)

Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report

Mehmet Erdem ÇAKMAK 1, Saltuk Buğra KAYA 1, Özge Can BOSTAN 1, Gülseren TUNCAY 1, Ebru DAMADOĞLU 1, Gül KARAKAYA 1, Ali Fuat KALYONCU 1,

1 Department of Chest Diseases, Division of Allergy and Clinical Immunology, Hacettepe University School of Medicine, Ankara, Turkey

DOI: 10.21911/aai.584
Viewed: 189
 - 
Downloaded : 79

Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.

Keywords : COVID-19, asthma, omalizumab, severe allergic asthma, anti-IgE